Involvement of eicosanoids in the pathogenesis of pancreatic cancer: The roles of cyclooxygenase-2 and 5-lipoxygenase

Table 1 Clinical trials

Drug	Type	Trial	Type	Cancer	Outcome	Toxicity
Celecoxib	COX-2 inhibitor	Uracil/Tegafur, Leucovorin, Celecoxib + RT[72]	II	Pancreatic; locally advanced unresectable	No significant partial or complete response	Significant GI toxicity
		Celecoxib, 5-FU[73]	Pilot study	Pancreatic; advanced after Gemcitabine treatment	Durable response	Well tolerated
		Gemcitabine, irinotecan, celecoxib[74]	II	Pancreatic; unresectable	Increased OS from 6 m to 18 m	Well tolerated
		Gemcitabine, celecoxib[76]	II	Pancreatic; locally advanced or metastatic	No significant response	Well tolerated
		Gemcitabine, cisplatin, celecoxib[75]	II	Pancreatic; metastatic	No significant response	Well tolerated
LY293111	LTB4 receptor antagonist	Irinotecan, LY293111[80]	I	Solid tumors (including pancreatic); locally advanced or metastatic	No significant response	Significant GI toxicity
		Gemcitabine, LY293111[81]	II	Pancreatic; locally advanced or metastatic	No significant response	Significant GI toxicity

Cox: Cyclooxygenase; LTB4: Leukotriene B4; RT: Radiation therapy; FU: Fluorouracil; OS: Overall survival; GI: Gastrointestinal.